A study to investigate the pharmacokinetics and safety of a single dose of duvakitug in healthy adult participants

2025-524617-84-00 Protocol PKM23567 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 9 Apr 2026 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol PKM23567

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 50
Countries 1
Sites 1

Healthy Volunteers

Key facts

Sponsor
Sanofi-Aventis Recherche & Developpement
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
9 Apr 2026 → ongoing
Decision date (initial)
2026-03-17
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2025-524617-84-00
WHO UTN
U1111-1330-1841

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy Volunteers

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sanofi-Aventis Recherche & Developpement

Sponsor organisation
Sanofi-Aventis Recherche & Developpement
Address
82 Avenue Raspail
City
Gentilly
Postcode
94250
Country
France

Scientific contact point

Organisation
Sanofi-Aventis Recherche & Developpement
Contact name
Clinical Sciences and Operations

Public contact point

Organisation
Sanofi-Aventis Recherche & Developpement
Contact name
Clinical Sciences and Operations

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruitment ended 50 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruitment ended
PAREXEL International GmbH
Parexel – Early Phase Clinical Unit Berlin, Klinikum Westend Haus 31, Spandauer Damm 130, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2026-04-09 2026-04-09 2026-04-30

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-01-26 Germany Acceptable
2026-03-13
2026-03-17
2 SUBSTANTIAL MODIFICATION SM-1 2026-04-02 Germany Acceptable
2026-04-22
2026-04-22